Skip to main content

The Use of Palliative Care in Organ Transplant Patients and End-of-Life Issues

  • Chapter
  • First Online:
Principles and Practice of Transplant Infectious Diseases

Abstract

Palliative care has been shown to improve quality of life and even prolong life in patients with certain types of malignancy and end-organ failure. Several studies have now demonstrated a beneficial impact of palliative care on the transplant patient. While hospice provides care for patients whose survival is expected to be less than 6 months, palliative care is the specialized care for the patient with serious illness and can be provided at any stage of the disease. All transplant candidates, by definition, qualify. Like transplant medicine, palliative care is also interdisciplinary. It is person/family centered and provides support along with aggressive symptom management. Patients are screened for pain and other physical symptoms as well as for psychosocial and spiritual distress. Palliative care also fosters communication between the patient/family and health-care providers. The patient’s values and principles are elicited so that concordant medical care is provided. Implementing palliative care, sometimes referred to as supportive care early in the disease trajectory has helped transition patients into hospice care once curative options have been exhausted. This chapter will elucidate why patients with organ failure who are candidates for transplantation or patients suffering from complications of transplantation are excellent candidates for palliative care and why a palliative care provider should be part of the transplant interdisciplinary team.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Health Resources and Services Administration, Organ Procurement and Transplantation Network. Available at: https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/

  2. Bloom RD, Goldberg LR, Wang AY, et al. An overview of solid organ transplantation. Clin Chest Med. 2005;26:529–43.

    Article  Google Scholar 

  3. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small cell lung cancer. N Engl Med. 2010;363(8):733–42.

    Article  CAS  Google Scholar 

  4. Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the project ENABLE II randomized controlled trial. JAMA. 2009;302:741–9.

    Article  CAS  PubMed Central  Google Scholar 

  5. World Health Organization. Available at: http://www.who.int/cancer/palliative/definition/en/

  6. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma – with particular reference to bronchogenic carcinoma. Cancer. 1948;1(4):634–56.

    Article  Google Scholar 

  7. Palliative Performance Scale (PPSv2) version 2. Medical Care of the Dying, 4th ed., p. 121. ©Victoria Hospice Society, 2006.

    Google Scholar 

  8. Jaarsma T, Beattie JM, Ryder M, Rutten FH, McDonagh T, Mohacsi P, Advanced Heart Failure Study Group of the HFA of the ESC, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the heart failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:433–43. European Society of Cardiology.

    Article  Google Scholar 

  9. Adler ED, Goldfinger JZ, Kalman J, et al. Contemporary reviews in cardiovascular medicine. Palliative care in the treatment of advanced heart failure. Circulation. 2009;120:2597–606.

    Article  Google Scholar 

  10. Hardin KA, Meyers M, Louie S. Integrating palliative Care in Severe Chronic Obstructive Lung Disease. COPD. 2008;5(4):207–20.

    Article  Google Scholar 

  11. Hope AA, Morrison RS. Integrating palliative care with chronic liver disease care. J Palliat Care. 2011;27(1):20–7.

    Article  Google Scholar 

  12. Holley JL. Palliative care in end-stage renal disease: illness trajectories, communication, and hospice use. Adv Chronic Kidney Dis. 2007;14(4):402–8.

    Article  Google Scholar 

  13. Singer PA, Martin DK, Kelner M. Quality end-of-life care: patents’ perspectives. JAMA. 1999;281:163–8.

    Article  CAS  Google Scholar 

  14. Teno JM, Clarridge BR, Casey V, et al. Family perspectives on end-of-life care at the last place of care. JAMA. 2004;291(1):88–93.

    Article  CAS  Google Scholar 

  15. Medicare part A: medicare hospice benefits. Available at: http://www.medicare.gov/Pubs/pdf/02154.pdf

  16. Higginson IJ, Sen-Gupta GJ. Place of care in advanced cancer qualitative systematic literature review of patient preferences. J Palliat Med. 2000;3(3):287–300.

    Article  CAS  Google Scholar 

  17. Murphy SL, Xu J, et al. Deaths: final data for 2015. National vital statistics report Vol 66. No 6 November 27, 2017.

    Google Scholar 

  18. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2018;137(25)

    Google Scholar 

  19. American Heart Association. Classes of heart failure. Available at: http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp

  20. Blinderman CD, Homel P, Billings JA, Portenoy RK, Tennstedt SL. Symptom distress and quality of life in patients with advanced heart failure. J Pain Symptom Manag. 2008;35(6):594–603.

    Article  Google Scholar 

  21. Levenson JW, McCarthy EP, Lynn J, et al. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc. 2000;48(5 Suppl):S101–9.

    Article  CAS  Google Scholar 

  22. Nordgren L, Sörensen S. Symptoms experienced in the last six months of life in patients with end-stage heart failure. Eur J Cardiovasc Nurs. 2003;2:213–7.

    Article  Google Scholar 

  23. Levy WC, Mozaffarian D, Linker DT, et al. The seattle heart failure model: prediction of survival in heart failure. Circulation. 2006;113(11):1424–33.

    Article  Google Scholar 

  24. Goda A, Williams P, Manicini D, et al. Selecting patients for heart transplantation: comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM). J Heart Lung Transplant. 2011;30(11):1236–43.

    Article  Google Scholar 

  25. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61.

    Article  Google Scholar 

  26. Schwarz ER, Baraghoush A, Morrissey RP, et al. Pilot study of palliative care consultation in patients with advanced heart failure referred for cardiac transplantation. J Palliat Med. 2012;15(1):12–5.

    Article  Google Scholar 

  27. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2018 report. www.goldcopd.org. Accessed 25 Sept 2018.

  28. GOLD. 2017 Global strategy for the diagnosis, management and prevention of COPD. http://goldcopd.org

  29. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38.

    Article  CAS  Google Scholar 

  30. Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:653–61.

    Article  PubMed Central  Google Scholar 

  31. Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez PR. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–31.

    Article  CAS  PubMed Central  Google Scholar 

  32. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med. 1996;154:959–67.

    Article  Google Scholar 

  33. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–52.

    Article  CAS  PubMed Central  Google Scholar 

  34. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax. 2000;55(12):1000–6.

    Article  CAS  PubMed Central  Google Scholar 

  35. Connor SR, Pyenson B, Flitch K, et al. Comparing hospice and nonhospice patient survival among patients who die within a three year window. J Pain Symptom Manage. 2007;33(3):238–46.

    Article  Google Scholar 

  36. Brumley R, Enguidanos S, Cherin D. Effectiveness of a homebase palliative care program for end-of-life. J Palliat Med. 2003;6:715–72438.

    Article  Google Scholar 

  37. Lanken PN, Terry PB, Delisser HM, Fahy BF, Hansen-Flaschen J, Heffner JE, et al. ATS end-of-life care task force. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illness. Am J Respir Crit Care Med. 2008;177(8):912–27.

    Article  Google Scholar 

  38. Zipprich A, Garcia-Tsao G, Rogowski S. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012;32(9):1407–14.

    Article  CAS  PubMed Central  Google Scholar 

  39. Llach J, Ginès P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988;94:482–7.

    Article  CAS  Google Scholar 

  40. Arroyo V, Gine SP, Alexander L. Definition and diagnostic criteria ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23(1):164–76.

    Article  CAS  Google Scholar 

  41. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.

    Article  CAS  Google Scholar 

  42. Lamba S, Murphy P, McVicker S. Changing end-of-life care practice for liver transplant service patients: structured palliative care intervention in the surgical intensive care unit. J Pain Symptom Manag. 2012;44(4):508–19.

    Article  Google Scholar 

  43. Singh N, Gayowski T, Wagener MM. Depression in patients with cirrhosis: impact on outcome. Dig Dis Sci. 1997;42(7):1421–7.

    Article  CAS  Google Scholar 

  44. Marchesini G, Bianchi G, Amodio P, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology. 2001;120(1):170–8.

    Article  CAS  Google Scholar 

  45. Roth K, Lynn J, Zhong Z, et al. Dying with end stage liver disease with cirrhosis: insights from SUPPORT. Study to understand prognoses and preferences for outcomes and risks of treatment. J Am Geriatr Soc. 2000;48(5 Suppl):S122–30.

    CAS  PubMed  Google Scholar 

  46. KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal Dialysis adequacy and vascular access. Am J Kidney Dis. 2006;48(suppl 1):S1–322.

    Google Scholar 

  47. Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005;454(4):658–66.

    Article  Google Scholar 

  48. The 2008 United States Renal Data System (USRDS) annual data report. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.

    Google Scholar 

  49. Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT. Physical symptoms and quality of life in patients on chronic dialysis: results of The Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD). Nephrol Dial Transplant. 1999;14:1163–70.

    Article  CAS  Google Scholar 

  50. Lee BO, Lin CC, Chaboyer W, Chiang CL, Hung CC. The fatigue experience of hemodialysis patients in Tai- wan. J Clin Nurs. 2007;16:407–13.

    Article  Google Scholar 

  51. McCann K, Boore JR. Fatigue in persons with renal failure who require maintenance haemodialysis. J Adv Nurs. 2000;32:1132–42.

    Article  CAS  Google Scholar 

  52. Kimmel PL, Emont SL, Newmann JM, Danko H, Moss AH. ESRD patient quality of life: symptoms, spiritual beliefs, psychosocial factors, and ethnicity. Am J Kidney Dis. 2003;42:713–21.

    Article  Google Scholar 

  53. Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Cruz I, Veis JH. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int. 2000;57:2093–8.

    Article  CAS  Google Scholar 

  54. Moreno F, Lopez Gomez JM, Sanz-Guajardo D, et al. Quality of life in dialysis patients. A Spanish multicentre study. Spanish Cooperative Renal Patients Quality of Life Study Group. Nephrol Dial Transplant. 1996;11(Suppl 2):125–9.

    Article  Google Scholar 

  55. Mingardi G, Cornalba L, Cortinovis E, et al. Health-related quality of life in dialysis patients. A report from an Italian study using the SF-36 Health Survey. DIA-QOL Group. Nephrol Dial Transplant. 1999;14(6):1503–10.

    Article  CAS  Google Scholar 

  56. Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in end stage renal disease patients. Am J Kidney Dis. 2001;38(3):443–64.

    Article  CAS  Google Scholar 

  57. Kasiske BL, Snyder JJ, Matas MD, Ellison MD, Gill JS, Kausz AT. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol. 2002;13:1358–64.

    Article  Google Scholar 

  58. Abecassis M, Bartlett ST, et al. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) conference. Clin J Am Soc Nephrol. 2008;3(2):471–80.

    Article  PubMed Central  Google Scholar 

  59. D’Souza A, Zhu X. Current uses and outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR summary slides; 2016. Available at: http://www.cibmtr.org

  60. American Society for Blood and Marrow Transplantation. Transplant referral guidelines. Available at: http://www.asbmt.org

  61. Saleh US, Brockopp DY. Quality of life one year following bone marrow transplantation: psychometric evaluation of the quality of life in bone marrow transplant survivors tool. Oncol Nurs Forum. 2001;28(9):1457–64.

    CAS  PubMed  Google Scholar 

  62. Andrykowski MA. Psychiatric and psychological aspects of bone marrow transplantation. Psychosomatics. 1994;35:13–24.

    Article  CAS  Google Scholar 

  63. Lesko LM. Psychiatric aspects of bone marrow transplantation: part I. Special issues during pre-transplant assessment and hospitalization. Psychooncology. 1993;2:161–83.

    Article  Google Scholar 

  64. Fife BL, Huster GA, Cornetta KG, Kennedy VN, Akard LP, Broun ER. Longitudinal study of adaptation to the stress of bone marrow transplantation. J Clin Oncol. 2000;18(7):1539–49.

    Article  CAS  Google Scholar 

  65. Baker F, Marcellus D, Zabora J, et al. Psychological distress among adult patients being evaluated for bone marrow transplantation. Psychosomatics. 1997;38:10–9.

    Article  CAS  Google Scholar 

  66. El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF, et al. Effect of inpatient palliative care on quality of life 2weeks after hematopoietic stem cell transplantation. JAMA. 2016;316(20):2094–103.

    Article  PubMed Central  Google Scholar 

  67. Lamon EB, Christakis NA. Some elements of prognosis in terminal cancer. Oncology (Willston Park). 1999;13(8):1165–70.

    Google Scholar 

  68. Heyland DK, Allan DE, Rocker G, et al. Discussing prognosis with patients and their families near the end of life: impact on satisfaction with end-of-life care. Open Med. 2009;3(2):e101–10.

    PubMed Central  PubMed  Google Scholar 

  69. Repetto L, Piselli P, Raffaele M, et al. Communicating cancer diagnosis and prognosis: when the target is the elderly patient-a GIOGER study. Eur J Cancer. 2009;45(3):374–83.

    Article  Google Scholar 

  70. SUPPORT Principal Investigators. A controlled trial to improve care for seriously ill hospitalized patients. JAMA. 1995;274:1591–8.

    Article  Google Scholar 

  71. Homsi J, Walsh D, Nelson KA, et al. The impact of palliative medicine consultation service in medical oncology. Support Care Cancer. 2002;10(4):337–42.

    Article  Google Scholar 

  72. Rich A. How long have I got? Prognostication and palliative care. Eur J Palliat Care. 1999;6:179–82.

    Google Scholar 

  73. Christakis N. Death Foretold: prophecy and prognosis in medical care. Chicago: Chicago University Press; 1999.

    Google Scholar 

  74. Virik K, Glare P. Validation of the palliative performance scale for inpatients admitted to a palliative care unit in Sydney, Australia. J Pain Symptom Manag. 2002;23(6):455–7.

    Article  Google Scholar 

  75. Olajide O, Hanson L, Usher BM, Qaqish BF, Schwartz R, Bernard S. Validation of the palliative performance scale in the acute tertiary care hospital setting. J Palliat Med. 2007;10(1):111–7.

    Article  Google Scholar 

  76. Harrold J, Rickerson E, Carroll JT, McGrath J, et al. Is the palliative performance scale a useful predictor of mortality in a heterogeneous hospice population? J Palliat Med. 2005;8(3):503–9.

    Article  Google Scholar 

  77. Head B, Ritchie CS, Smoot TM. Prognostication in hospice care: can the palliative performance scale help? J Palliat Med. 2005;8(3):492–502.

    Article  Google Scholar 

  78. Morita T, Tsunod J, Inoue S, et al. Validity of the palliative performance scale from a survival perspective. J Pain Symptom Manag. 1999;18(1):2–3.

    Article  CAS  Google Scholar 

  79. Poses RM, Smith WR, McClish DK, et al. Physicians’ survival predictions for patients with acute congestive heart failure. Arch Intern Med. 1997;157(9):1001–7.

    Article  CAS  Google Scholar 

  80. National Hospice and Palliative Care Organization (NHPCO). https://www.nhpco.org/

  81. National Hospice and Palliative Care Organization. Medical guidelines for determining prognosis in selected non-cancer diseases, 2nd ed. Arlington: National Hospice Organization; 1997, J Pain Palliat Care Pharmacother. 1996;11(2).

    Google Scholar 

  82. Brumley RD, Enguidanos S, Cherin DA. Effectiveness of a home-based palliative care program for end-of-life. J Palliat Med. 2003;6:715–24.

    Article  Google Scholar 

  83. O’Brien T, Welsh J, Dunn FG. ABC of palliative care. Non malignant conditions. BMJ. 1998;316(7127):286–9.

    Article  PubMed Central  Google Scholar 

  84. Janssen DJ, Spruit MA, Wouters EF, Schols JM. Daily symptom burden in end-stage chronic organ failure: a systematic review. Palliat Med. 2008;22:938–48.

    Article  CAS  Google Scholar 

  85. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag. 2006;31:58–69.

    Article  Google Scholar 

  86. Schickedanz A, Schillinger D, Landefeld CS. A clinical framework for improving the advance care planning process: start with patient’ self-identified barriers. J Am Geriatr Soc. 2009;57(1):31–9; quiz 62.

    Article  PubMed Central  Google Scholar 

  87. Wright L, Pape D, Ross K, Campbell M, Bowman K. Approaching end-of-life care in organ transplantation: the impact of transplant patients’ death and dying. Prog Transplant. 2007;17(1):57–61.

    Article  Google Scholar 

  88. Gourdji I, McVey L, Purden M. A quality end of life from a palliative care patient’s perspective. J Palliat Care. 2009;25(1):40–50.

    Article  Google Scholar 

  89. Hanson LC, Danis M, Garrett J. What is wrong with end-of-life care? Opinions of bereaved family members. J Am Geriatr Soc. 1997;45(11):1339–44.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joseph Lowy .

Editor information

Editors and Affiliations

Appendix

Appendix

Karnofsky Performance Status

100

Normal, no complaints, no evidence of disease

90

Able to carry on normal activity, some minor symptoms of disease

80

Normal activity with effort: some symptoms of disease

70

Able to care for self but unable to carry on normal activity or active work

60

Requires occasional assistance but is able to care for most of personal needs

50

Requires considerable assistance and frequent medical care

40

Disabled: requires special care and assistance

30

Severely disabled: hospitalization is indicated, death not imminent

20

Very sick, hospitalization necessary: active treatment necessary

10

Moribund, fatal processes progressing rapidly

0

Death

Palliative Performance Scale (PPSv2) [87] Reprinted with permission from Victoria Hospice Society , BC, Canada (2001) www.victoriahospice.org

 

Ambulation

Activity and evidence of disease

Self-Care

Intake

Conscious level

100%

Full

Normal activity and work. No evidence of disease

Full

Normal

Full

90%

Full

Normal activity and work. Some evidence of disease

Full

Normal

Full

80%

Full

Normal activity with effort. Some evidence of disease

Full

Normal or reduced

Full

70%

Reduced

Unable normal job/work. Significant disease

Full

Normal or reduced

Full

60%

Reduced

Unable hobby/house work. Significant disease

Occasional assistance necessary

Normal or reduced

Full or confusion

50%

Mainly sit/lie

Unable to do any work. Extensive disease

Considerable assistance required

Normal or reduced

Full or confusion

40%

Mainly in bed

Unable to do most activity. Extensive disease

Mainly assistance

Normal or reduced

Full or drowsy +/− confusion

30%

Totally bed bound

Unable to do any activity. Extensive disease

Total care

Normal or reduced

Full or drowsy +/− confusion

20%

Totally bed bound

Unable to do any activity. Extensive disease

Total care

Minimal to sips

Full or drowsy +/− confusion

10%

Totally bed bound

Unable to do any activity. Extensive disease

Total care

Mouth care only

Drowsy or coma +/− confusion

0%

Death

Instructions for Use of PPS (See also Definition of Terms)

  1. 1.

    PPS scores are determined by reading horizontally at each level to find a “best fit” for the patient which is then assigned as the PPS% score.

  2. 2.

    Begin at the left column and read downwards until the appropriate ambulation level is reached, then read across to the next column and downwards again until the activity/evidence of disease is located. These steps are repeated until all five columns are covered before assigning the actual PPS for that patient. In this way, “leftward” columns (columns to the left of any specific column) are “stronger” determinants and generally take precedence over others.

    • Example 1: A patient who spends the majority of the day sitting or lying down due to fatigue from advanced disease and requires considerable assistance to walk even for short distances but who is otherwise fully conscious level with good intake would be scored at PPS 50%.

    • Example 2: A patient who has become paralyzed and quadriplegic requiring total care would be PPS 30%. Although this patient may be placed in a wheelchair (and perhaps seem initially to be at 50%), the score is 30% because he or she would be otherwise totally bed bound due to the disease or complication if it were not for caregivers providing total care including lift/transfer. The patient may have normal intake and full conscious level. Example 3: However, if the patient in example 2 was paraplegic and bed bound but still able to do some self-care such as feed themselves, then the PPS would be higher at 40 or 50% since he or she is not “total care”.

  3. 3.

    PPS scores are in 10% increments only. Sometimes, there are several columns easily placed at one level but one or two which seem better at a higher or lower level. One then needs to make a “best fit” decision. Choosing a “half-fit” value of PPS 45%, for example, is not correct. The combination of clinical judgment and “leftward precedence” is used to determine whether 40 or 50% is the more accurate score for that patient.

  4. 4.

    PPS may be used for several purposes. First, it is an excellent communication tool for quickly describing a patient’s current functional level. Second, it may have value in criteria for workload assessment or other measurements and comparisons. Finally, it appears to have prognostic value.

Copyright © 2001 Victoria Hospice Society

Definition of Terms for PPS

As noted below, some of the terms have similar meanings with the differences being more readily apparent as one reads horizontally across each row to find an overall “best fit” using all five columns.

  1. 1.

    Ambulation

    The items mainly sit/lie, mainly in bed, and totally bed bound are clearly similar. The subtle differences are related to items in the self-care column. For example, “totally bed ‘bound’ at PPS 30% is due to either profound weakness or paralysis such that the patient not only can’t get out of bed but is also unable to do any self-care. The difference between ‘sit/lie’ and ‘bed’ is proportionate to the amount of time the patient is able to sit up vs need to lie down.”

    Reduced ambulation is located at the PPS 70% and PPS 60% level. By using the adjacent column, the reduction of ambulation is tied to inability to carry out their normal job, work occupation or some hobbies or housework activities. The person is still able to walk and transfer on their own but at PPS 60% needs occasional assistance.

  2. 2.

    Activity and Extent of disease

    Some, significant, and extensive disease refer to physical and investigative evidence which shows degrees of progression. For example in breast cancer, a local recurrence would imply “some” disease; one or two metastases in the lung or bone would imply “significant” disease, whereas multiple metastases in the lung, bone, liver, brain, hypercalcemia, or other major complications would be “extensive” disease. The extent may also refer to progression of disease despite active treatments. Using PPS in AIDS, “some” may mean the shift from HIV to AIDS, and “significant” implies progression in physical decline, new or difficult symptoms, and laboratory findings with low counts. “Extensive” refers to one or more serious complications with or without continuation of active antiretrovirals, antibiotics, etc.

    The above extent of disease is also judged in context with the ability to maintain one’s work and hobbies or activities. Decline in activity may mean the person still plays golf but reduces from playing 18 holes to 9 holes, or just a par 3, or to backyard putting. People who enjoy walking will gradually reduce the distance covered, although they may continue trying, sometimes even close to death (e.g., trying to walk the halls).

  3. 3.

    Self-Care

    Occasional assistance means that most of the time patients are able to transfer out of bed, walk, wash, go to toilet, and eat by their own means but that on occasion (perhaps once daily or a few times weekly) they require minor assistance.

    Considerable assistance means that regularly every day, the patient needs help, usually by one person, to do some of the activities noted above. For example, the person needs help to get to the bathroom but is then able to brush his or her teeth or wash at least hands and face. Food will often need to be cut into edible sizes but the patient is then able to eat of his or her own accord.

    Mainly assistance is a further extension of “considerable.” Using the above example, the patient now needs help getting up but also needs assistance washing his face and shaving, but can usually eat with minimal or no help. This may fluctuate according to fatigue during the day.

    Total care means that the patient is completely unable to eat without help, go to toilet, or do any self-care. Depending on the clinical situation, the patient may or may not be able to chew and swallow food once prepared and fed to him or her.

  4. 4.

    Intake

    Changes in intake are quite obvious with normal intake referring to the person’s usual eating habits while healthy. Reduced means any reduction from that and is highly variable according to the unique individual circumstances. Minimal refers to very small amounts, usually pureed or liquid, which are well below nutritional sustenance.

  5. 5.

    Conscious Level

    Full consciousness implies full alertness and orientation with good cognitive abilities in various domains of thinking, memory, etc. Confusion is used to denote presence of either delirium or dementia and is a reduced level of consciousness. It may be mild, moderate or severe with multiple possible etiologies. Drowsiness implies either fatigue, drug side effects, delirium, or closeness to death and is sometimes included in the term stupor. Coma in this context is the absence of response to verbal or physical stimuli; some reflexes may or may not remain. The depth of coma may fluctuate throughout a 24-h period.

© Copyright Notice.

The Palliative Performance Scale version 2 (PPSv2) tool is copyright to Victoria Hospice Society and replaces the first PPS published in 1996 [J Pall Care 9(4): 26-32]. It cannot be altered or used in any way other than as intended and described here. Programs may use PPSv2 with appropriate recognition. Available in electronic Word format by email request to edu.hospice@viha.ca

Correspondence should be sent to Director Education and Research, Victoria Hospice Society, 1952 Bay Street, Victoria, BC, V8R 1J8, Canada

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ayala, J.S., Lowy, J. (2019). The Use of Palliative Care in Organ Transplant Patients and End-of-Life Issues. In: Safdar, A. (eds) Principles and Practice of Transplant Infectious Diseases. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-9034-4_60

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9034-4_60

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-9032-0

  • Online ISBN: 978-1-4939-9034-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics